Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
Completed · Phase 3
Conditions studied: HIV Infections
In brief
Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside reverse transcriptase inhibitors (NRTIs).
Key facts
- Study ID
- NCT00120393
- Run by
- Bristol-Myers Squibb
- People needed
- 192
- Starts
- 2004-01-01
- Expected to finish
- 2006-05-01
- Last updated by the study team
- 2010-02-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- HIV positive
- LPV/RTV-based HAART for at least 6 months
- HIV-1 RNA less than 50c/mL (confirmed)
- Non-HDL higher than 160 mg/dL
- CD4 of at least 50 cells/mL
You may not qualify if…
- Use of lipid-lowering agents
Where it is running
- Local Institution — Phoenix, Arizona, United States
- Local Institution — Bakersfield, California, United States
- Local Institution — Los Angeles, California, United States
- Local Institution — San Francisco, California, United States
- Local Institution — Miami, Florida, United States
- Local Institution — Boston, Massachusetts, United States
- Local Institution — New York, New York, United States
- Local Institution — Cincinnati, Ohio, United States
- Local Institution — Portland, Oregon, United States
- Local Institution — Philadelphia, Pennsylvania, United States
- Local Institution — Columbia, South Carolina, United States
- Local Institution — Dallas, Texas, United States
- Local Institution — Hamilton, Ontario, Canada
- Local Institution — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.